AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06332963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floatation-REST
Description: Participants lay supine in one of two circular fiberglass pools that were custom-designed for research purposes. The floatation pools are 8 feet in diameter and contain 11 inches of reverse osmosis water saturated with \~1,800 pounds of Epsom salt (magnesium sulfate). This creates a dense saltwater solution with a specific gravity of \~1.26, allowing participants to effortlessly float on their back while the water hovers just above the ears. The temperature of the water and air is calibrated to approximate skin temperature (\~95.0 °F), helping to minimize the need for thermoregulation while reducing the boundary between air, body, and water. Clothing is usually not worn while floating since anything touching the body can generate somatosensory stimulation, detracting from the float experience. However, participants have the option to choose if they would prefer to float with a bathing suit or nude. During floatation-REST, visual, auditory, olfactory stimuli are minimized.
Study NCT06780189 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Extraction and Post-Procedure Monitoring Under Sedation in Children Not Exposed to Passive Smoking
Description: This study is designed to measure the differences in vital parameters of children undergoing deep sedation who are not exposed to passive cigarette smoke at home. Furthermore, the study aims to comprehensively evaluate and document the entire treatment process from start to finish using the RASS, MASS, and PAED scales for postoperative assessment.
Study NCT06332963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IFT
Description: Two ACT principles, contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the IFT condition, awareness and acceptance of bodily signals, thoughts, and emotions and being present with one's self (i.e., mindfulness focus is inward) are emphasized. All participants will engage in an introduction session. Followed by three IFT sessions. The experimental sessions are formatted the same for both conditions. Each begins with a clinician reviewing previous constructs and introducing a new skill. Then participants engage in their assigned condition intervention, followed by a debrief with a clinician. Practices in both conditions are matched as closely as possible for content. The mindful focus of IFT is internal toward thoughts, emotions, and body sensations. In the experimental sessions, participants will engage in a floatation-REST session while practicing acceptance and mindfulness-based skills presented to them.
Study NCT06332963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EFT
Description: Two acceptance and commitment therapy modules contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the EFT condition, awareness and acceptance of thoughts and emotions and mindfulness of current experience are emphasized. The mindful focus of EFT is external, toward attending to experience as well as thoughts and emotions. During experimental sessions, participants will engage in a self-guided and computer-based practice of acceptance and mindfulness-based skills. These videos were created to ensure content was congruent with the material presented in the introduction sessions and represent skills that build from session to session.
Study NCT06173752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Participants will complete exposure therapy for up to 12 weeks, and coached exposure session will be approximately 50 minutes.
Study NCT05955027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: a drug to treat influenza, oral
Study NCT05955027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo control, oral
Study NCT05955027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo control, oral
Study NCT06208709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: carpal arch space augmentation (CASA)
Description: A BOA brace with a balloon that is affixed internally. The device applies a small cyclic force of to the wrist. The cycles include a brief period of force applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep.
Study NCT06208709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC)
Description: A BOA brace that can be adjusted to the arm of the participant.
Study NCT06055699 — intervention group
Intervention type: OTHER
Intervention: Fecal sampling
Description: Stool samples are a collection of products derived from the human body that is not invasive in any way and samples not taken as part of usual care.~Stool samples will be collected at home within 7 days of the visit M0, M3 and M6 and within 14 days of the visit M12 in an ethanol tube and in DNA/RNA shield, and transported at room temperature to Saint-Antoine Hospital (CRB SAT, AP-HP, Pr. SIMON ), samples will be aliquoted (3 aliquots per tubes) and stored at -80°C for a period of 5 years (renewable) At the end of the research, stool samples will be analysed using metagenomics sequencing.~DNA extraction will be performed following the standards of the The International Human Microbiome Standards . DNA will be stored at -80°C.
Study NCT06055699 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood samples (serum, 15 ml) are an additional and minimal collection performed following a sample taken as part of usual care.~Blood samples (serum) will be collected during the visit at M0, M3 (± 7 days), M6 (± 7 days) and M12 (± 7 days).~In the hours following collection, the samples must be aliquoted and stored at -80°C in a secure place in the participating centre.
Study NCT04072640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200mg
Description: Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
Study NCT04072640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amphotericin B deoxycholate (0.4-0.5mg/kg/d)
Description: Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
Study NCT04072640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)
Description: Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
Study NCT05441345 — intervention group
Intervention type: OTHER
Intervention: questionnaires with collection of stool and urine
Description: questionnaires will be completed (GPAQ, SarQoL, EQ-5D-3L, SF36), with collection of stool (for care and research) and urine
Study NCT04442581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT04442581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04275752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Perform endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training twice a week for a period of one hour per session, for a total of 16 sessions.
Study NCT06128512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch containing the needle will remain in place until the student completes the examination.
Study NCT06128512 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular acupuncture
Description: Sham Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, without a needle. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch will remain in place until the student completes the examination.
Study NCT05604105 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.
Study NCT04309721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
Study NCT04309721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
Study NCT06780826 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle
Study NCT06780826 — intervention group
Intervention type: DRUG
Intervention: Etoposide
Description: Etoposide,intravenous infusion, 100mg/m,21 days per cycle
Study NCT06780826 — intervention group
Intervention type: DRUG
Intervention: Carboplatin
Description: carboplatin,intravenous infusion, AUC=5, 21 days per cycle.
Study NCT06780163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-estradiol 10 mcg
Description: 17β-estradiol 10 mcg will be given to all participants. The participants will be asked to use 1 tab daily for 2 weeks vaginally before bed, then 1 tab twice a week vaginally before bed until 12 weeks
Study NCT06780358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI supported detection of bladder cancer
Description: AI-model-supported detection of bladder cancer during white light cystoscopy
Study NCT05795660 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: platelet rich plasma
Description: platelet rich plasma injection
Study NCT05795660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: platelet rich plasma injection
Study NCT05698992 — intervention group
Intervention type: OTHER
Intervention: evidence-based individualized rehabilitation
Description: The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
Study NCT06488222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects will receive 40 mg docetaxel intravesically.
Study NCT06488222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Subjects will receive 1 mg gemcitabine intravesically.
Study NCT04747626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-SAFER
Description: Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
Study NCT05566054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 10mg orally daily for 7 days (d1-d7)
Study NCT05566054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: azacytidine 75mg/m2 daily for 7 days (d1-d7)
Study NCT05566054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacytidine 75mg/m2 daily for 7 days (d1-d7)
Study NCT05566054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
Study NCT04907604 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: A multi-modal and integrative e-health platform aimed at promoting health and reducing the negative impact of mental problems in the workplace
Description: It addresses six main domains: improving awareness of mental health problems and reducing stigma; reducing psychosocial risk factors in the workplace; improving wellbeing and reducing psychological symptoms; ensuring early detection of mental disorders; promoting healthy behaviours and lifestyles; and facilitating early return to work.
Study NCT05151744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamikibart
Description: Vamikibart will be administered by IVT injection in the study eye.
Study NCT05151744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab will be administered by IVT injection in the study eye.
Study NCT05151744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab will be administered by IVT injection in the study eye.
Study NCT05151744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
Study NCT06447181 — intervention group
Intervention type: DEVICE
Intervention: 3D visualization technology ; ICG fluorescence technology .
Description: Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step.~ICG fluorescence technology is a fluorescent laparoscopic technology that can detect extrahepatic biliary duct misalignment, improving surgical precision and safety.
Study NCT05649358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lactate sensor (Lactisense)
Description: Non-invasive monitoring of interstitial lactate levels during and after exercise.
Study NCT06781970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vitamin C
Description: Patients will be given 500 mg of oral vitamin C, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
Study NCT06781970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be given placebo, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
Study NCT06781970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will be given placebo, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
Study NCT06779851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPT567
Description: Immunocytokine infusion
Study NCT06780904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Treatment protocol:~1. Dry needling: Prone position, identify trigger points in upper trapezius, use Hong technique with 50mm/0.25 gauge needle, eliciting local twitch response.~2. Passive stretching: Supine position, cervical spine stretched just short of restriction, hold for 30s with 20s rest, repeat 3 times.~3. Muscle Energy Technique: Supine position, identify restriction barrier, move spine away from barrier, instruct patient to isometrically contract opposing movement (25% strength), hold for 7-10s, then stretch towards new barrier for 30s, repeat 3 times.
Study NCT06780904 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dry Needling
Description: Treatment protocol:~1. Dry needling: Prone position, identify trigger points in upper trapezius, use Hong technique with 50mm/0.25 gauge needle, eliciting local twitch response.~2. Passive stretching: Supine position, cervical spine stretched just short of restriction, hold for 30s with 20s rest, repeat 3 times.~3. Muscle Energy Technique: Supine position, identify restriction barrier, move spine away from barrier, instruct patient to isometrically contract opposing movement (25% strength), hold for 7-10s, then stretch towards new barrier for 30s, repeat 3 times.
Study NCT06779929 — intervention group
Intervention type: DRUG
Intervention: Tirzepatide
Description: Tirzepatide
Study NCT06779929 — intervention group
Intervention type: DRUG
Intervention: Dulaglutide
Description: Dulaglutide
Study NCT06780865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine
Description: Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.
Study NCT06780865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-controlled group
Description: Participants are treated with corresponding placebo
Study NCT03474718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma Left Side
Description: Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
Study NCT03474718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma Right Side
Description: Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
Study NCT06569537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: 4%
Study NCT05777759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lyft with Lidocaine
Description: hyaluronic acid
Study NCT05777759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Voluma XC
Description: hyaluronic acid
Study NCT06569537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLT
Description: Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
Study NCT04874038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 20mg/ml
Description: Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).
Study NCT04874038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
Study NCT04649710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days
Study NCT04649710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT04647019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild blueberry powder
Description: 22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder consumed daily with 250 ml water. The powder is sealed in sachets and stored at -24 °C, except when transported. Participants are asked to store the sachets in a freezer until consumption.
Study NCT04647019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: 22 g placebo powder matched for macronutrients, color, and flavor consumed daily with 250 ml water. The powder is sealed in sachets and participants are asked to store the sachets in a freezer until consumption.
Study NCT05090982 — intervention group
Intervention type: OTHER
Intervention: Audio recordings during the consultations
Description: 50 patients with audio recordings of the consultation
Study NCT05090982 — intervention group
Intervention type: OTHER
Intervention: Audio recordings during the consultations and test of the shared medical decision-making tool for modification
Description: 50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification
Study NCT05566054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
Study NCT06221254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COBMINDEX digital application
Description: COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques and practices using digital application.
Study NCT06512480 — intervention group
Intervention type: PROCEDURE
Intervention: colonic resection
Description: colonic resection with the Hugo RAS robotic platform.
Study NCT05090982 — intervention group
Intervention type: OTHER
Intervention: Audio recordings during the consultations and test of the shared medical decision-making tool for validation
Description: 50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.